On January 7, 2021 Cancer Genetics, Inc. (the "Company") (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, reported that Jay Roberts, Chief Executive Officer, will present at the 2021 BioConnect Virtual Conference hosted by H.C. Wainwright (Press release, Cancer Genetics, JAN 7, 2021, View Source [SID1234573631]). Registered attendees can access the recorded presentation on-demand (24×7) for the duration of the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Date: January 11-14, 2021 (Monday-Thursday)
On-Demand Starts: 6:00am ET – Monday, January 11, 2021
On-Demand Ends 9:00pm ET- Thursday, January 14, 2021
Registration: View Source
Mr. Roberts will highlight the Company’s recent transformational business strategy, discuss near-term events including the Company’s proposed merger with StemoniX, Inc., and the broader corporate vision of the Company going forward.

CGIX will be available for virtual 1:1 meetings both during and after the BioConnect Conference. Please contact Jennifer K. Zimmons, Ph.D. [email protected] 917.214.3514 for scheduling.

On January 7, 2021 Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported that Michele Garufi, Chairman and Chief Executive Officer of Nicox, will present in a fireside chat at the H.C. Wainwright BioConnect Conference being held virtually on January 11-14, 2021 (Press release, NicOx, JAN 7, 2021, https://www.nicox.com/news-media/nicox-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference/ [SID1234573630]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A video webcast of Nicox’s presentation will be available on-demand from Monday January 11 at 6:00 a.m. EST for one week by clicking here and accessible on Nicox’s website (www.nicox.com) in the "Presentations & Events" section. The video webcast will be available for 90 days.

On January 7, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this month. The Infinity leadership team also will be available for one-on-one meetings during the investor conferences on January 7-8 and 11-14, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for all three investor conferences are as follows:

39th Annual J.P. Morgan Healthcare Conference – Corporate Presentation

Date:

January 14, 2021

Time:

2:00 p.m. ET

Webcast:

Audio-only Link to Webcast Here

2021 LifeSci Advisors – Corporate Access Event

Date:

January 7-13, 2021

Time:

Management available for 1×1 meetings

H.C. Wainwright BioConnect 2021 Conference – Corporate Presentation

Date:

January 11-14, 2021

The session time is on-demand, beginning Monday January 11 starting 6:00 a.m. ET.

To register and view the presentation, please click here.

A replay for all conferences will be available on the Events and Presentations section investor section of the Infinity Pharmaceuticals website View Source following the conference.

On January 7, 2021 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference (Press release, Zymeworks, JAN 7, 2021, View Source [SID1234573628]). In addition, Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI) and provide an update on ZW49’s clinical progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan Healthcare Conference Presentation

The J.P. Morgan presentation will take place on Monday, January 11, 2021 at 3:40 p.m. ET.

Zanidatamab ASCO (Free ASCO Whitepaper) GI Webcast

Zymeworks will host a webcast on Friday, January 15, 2021 at 5:00 pm ET to discuss the clinical results for the Company’s HER2 bispecific, zanidatamab, in biliary tract cancer and gastroesophageal cancer presented at ASCO (Free ASCO Whitepaper) GI earlier that day. The data will be discussed by lead investigator, Dr. Funda Meric-Bernstam, M.D., Clinical Investigator and Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

ZW49 Clinical Update Webcast

Zymeworks will host a webcast on Wednesday, January 27, 2021 at 4:30 pm ET to provide an update on clinical progress from the Phase 1 dose-escalation study for the Company’s HER2 bispecific antibody-drug conjugate, ZW49.

Interested parties can access these live webcasts via a link from Zymeworks’ website at View Source Participants are encouraged to connect five to ten minutes prior to the scheduled start time. A recorded replay will also be available on the website shortly after the webcast concludes.

On January 7, 2021 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference. Details are as follows (Press release, Syros Pharmaceuticals, JAN 7, 2021, View Source [SID1234573627]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

39th Annual J.P. Morgan Healthcare Conference:
Date: Thursday, January 14
Time: 2:50 p.m. ET

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.